Xulane Patch
Product Images NDC 0378-3340

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Xulane (NDC 0378-3340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chance Of Getting Pregnant (Image 01)

A vertical arrow chart illustrating pregnancy rates per 100 women in one year correlated with various birth control methods. The chart lists methods from fewer to more pregnancies, including implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal rings with hormones, condoms, diaphragm, abstinence during fertile days, spermicide, withdrawal, and no birth control.*

FDA Label Image

Choosing A Place On The Body For The Patch (Image 02)

Instructional images showing application sites for the XULANE transdermal patch. The patch is demonstrated applied on the upper arm, lower abdomen, side of the hip, and upper back of a female model, illustrating appropriate body locations for use.*

FDA Label Image

How To Apply The Patch Figure 01 (Image 03)

An instructional illustration showing a person's hands removing a XULANE transdermal patch from its foil packaging. The image demonstrates the preparation step for applying the patch containing norelgestromin and ethinyl estradiol.*

FDA Label Image

How To Apply The Patch Figure 02 (Image 04)

An image showing hands applying the XULANE transdermal patch, which contains norelgestromin and ethinyl estradiol. The patch is being placed on the skin with a protective backing partially removed, demonstrating proper application technique.*

FDA Label Image

How To Apply The Patch Figure 03 (Image 05)

A black-and-white instructional illustration showing a person applying a XULANE transdermal patch to the skin on the abdomen. The image focuses on hands placing the rectangular patch, which is clear with a visible white backing, onto the skin.*

FDA Label Image

How To Apply The Patch Figure 04 (Image 06)

An illustration showing a transdermal patch being applied to the skin on the lower abdomen. The hands in the image are positioning the rectangular patch flat against the skin surface as part of the administration process.*

FDA Label Image

Figure 1: Likelihood Of Developing A Vte Within One Year Among Pregnant And Non-pregnant Women (Image 07)

A horizontal bar chart illustrating the number of women with a blood clot per 10,000 woman-years across four groups: Non-CHC User Non-Pregnant, CHC User, Pregnancy, and Postpartum (12 weeks only). Each bar is separated into shaded and unshaded segments, with ranges noted for each group, showing increased blood clot incidence from Non-CHC Users to Postpartum women.*

FDA Label Image

Norelgestromin And Ethinyl Estradiol Structural Formula (Image 08)

Chemical structure diagram showing the molecular structures of norelgestromin and ethinyl estradiol, the active ingredients in the product XULANE. The left structure depicts norelgestromin, and the right structure depicts ethinyl estradiol.*

FDA Label Image

Figure 2: Mean Serum Ngmn Concentrations (ng/ml) In Healthy Female Volunteers Following Application Of Norelgestromin And Ethinyl Estradiol Transdermal System On The Buttock For Three Consecutive Cycles (vertical Arrow Indicates Time Of Patch Removal) (Image 09)

A line graph depicting NGMN concentration (ng/mL) over time (hours) for XULANE transdermal patch in different menstrual cycles and weeks. The graph shows concentration curves for Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3, illustrating drug concentration changes over 240 hours.*

FDA Label Image

Figure 3: Mean Serum Ee Concentrations (pg/ml) In Healthy Female Volunteers Following Application Of Norelgestromin And Ethinyl Estradiol Transdermal System On The Buttock For Three Consecutive Cycles (vertical Arrow Indicates Time Of Patch Removal.) (Image 10)

A line graph depicting the EE (ethinyl estradiol) concentration (pg/mL) over time (hours) for XULANE transdermal patch in different cycles and weeks. Concentration is plotted on the vertical axis and time on the horizontal, showing data points for Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3 with distinct markers.*

FDA Label Image

Figure 4: Mean Serum Concentration-time Profiles Of Ngmn Following Once-daily Administration Of An Oral Contraceptive For Two Cycles Or Application Of Norelgestromin And Ethinyl Estradiol Transdermal System For Two Cycles To The Buttock In Healthy Female Volunteers. [oral Contraceptive: Cycle 2, Days 15 To 21, Norelgestromin And Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] (Image 11)

A line graph comparing norelgestromin concentration (ng/mL) over time (hours) for a transdermal system applied to the buttock versus an oral contraceptive with norelgestromin 250 µg and ethinyl estradiol 35 µg. The graph shows sustained levels from the patch and a sharp peak then decline from the oral dose by 240 hours.*

FDA Label Image

Figure 5: Mean Serum Concentration-time Profiles Of Ee Following Once-daily Administration Of An Oral Contraceptive For Two Cycles Or Application Of Norelgestromin And Ethinyl Estradiol Transdermal System For Two Cycles To The Buttock In Healthy Female Volunteers. [oral Contraceptive: Cycle 2, Days 15 To 21, Norelgestromin And Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] (Image 12)

A line graph depicting ethinyl estradiol (EE) concentration levels (pg/mL) over time (hours) up to 240 hours for the norelgestromin and ethinyl estradiol transdermal system applied to the buttock. The chart compares oral contraceptive administration with the transdermal system, including estimated steady state data based on day 21.*

FDA Label Image

Xulane Transdermal System 150/35 Mcg Per Day Carton (Image 13)

Packaging label for Xulane 150/35 mcg per day transdermal patch, containing norelgestromin and ethinyl estradiol. The label indicates a package with 3 transdermal systems, manufactured by Mylan Pharmaceuticals Inc. It includes usage instructions, storage conditions, and a dosing day checklist. The label also states it is for prescription use only and for transdermal application.*

FDA Label Image

Patch Calendar (Image 14)

A calendar-style diagram illustrating a 4-week schedule for using XULANE transdermal patches. It marks Days 1, 8, and 15 as Weeks 1, 2, and 3 with an arrow extending across the week, and Week 4 is labeled with 'NO PATCH' inside a box with an X, indicating no patch use during that week.*

FDA Label Image

Likelihood Of Developing A Serious Blood Clot (venous Thromboembolism [vte]) (Image 15)

A horizontal bar chart comparing the number of women with a blood clot per 10,000 woman-years across four groups: Non-CHC users who are non-pregnant, CHC users, pregnant women, and women postpartum within 12 weeks. Each group shows ranges with shaded and unshaded bars representing different risk intervals, with postpartum women having the highest range of 40 to 65 events.*

FDA Label Image

Instructions For Use Figure A (Image 16)

An instructional illustration showing two hands holding a partially opened XULANE transdermal patch foil pouch. The image demonstrates the initial step in removing the patch from its packaging for application.*

FDA Label Image

Instructions For Use Figure B (Image 17)

Illustration showing a hand holding a rectangular transdermal patch, likely representing the XULANE patch, used for delivering norelgestromin and ethinyl estradiol transdermally.*

FDA Label Image

Instructions For Use Step 1 (Image 18)

A series of four black-and-white photos showing a female model applying a XULANE transdermal patch at different body locations. The patch is visibly placed on the upper arm, lower abdomen, buttock, and upper back, illustrating possible application sites for the norelgestromin and ethinyl estradiol patch.*

FDA Label Image

Instructions For Use Step 2 Figure 1 (Image 19)

An instructional illustration showing hands peeling back the protective backing of a XULANE transdermal patch. The image demonstrates how to properly open the patch packaging before application to the skin.*

FDA Label Image

Instructions For Use Step 2 Figure 2 (Image 20)

An illustration showing two hands holding a transparent transdermal patch, likely representing the XULANE contraceptive patch containing norelgestromin and ethinyl estradiol. The image highlights the patch's size and application form.*

FDA Label Image

Instructions For Use Step 2 Figure 3 (Image 21)

An instructional illustration showing a person applying a XULANE transdermal patch to the skin on the abdomen. The image displays hands holding and pressing the patch onto the skin surface.*

FDA Label Image

Instructions For Use Step 2 Figure 4 (Image 22)

An instructional image showing hands applying a XULANE transdermal patch to the skin on the abdomen. The patch is a small, square adhesive designed for continuous delivery of norelgestromin and ethinyl estradiol.*

FDA Label Image

Image 23

A forest plot displaying effect estimates (odds ratios or relative risks) with 95% confidence intervals from eight different studies comparing ever use and current use of a contraceptive method. The x-axis represents the effect estimate scale from -1.5 to 2. Each study's effect estimate and confidence interval are plotted as dots with horizontal lines, with data labels included for effect estimates and confidence intervals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.